Literature DB >> 8133976

Ondine's curse: a discussion of five cases.

M C Commare1, B François, B Estournet, A Barois.   

Abstract

Five cases of central congenital hypoventilation, Ondine's curse, were studied. The diagnostic criteria were: lack of respiratory autonomy during sleep, abnormal CO2 test results and abnormal respiratory monitoring results during sleep. This hypoventilation induced chronic complications, such as a pulmonary arterial hypertension and psychomotor and/or growth retardation. The other conditions frequently associated with Ondine's curse were: brainstem disturbances, Hirschsprung disease and neuroblastoma. Since other brainstem dysfunctions are sometimes associated with hypoventilation and because complications can arise, these children routinely underwent complementary investigations. Treatment was symptomatic. Assisted mechanical ventilation was initiated as soon as possible and carefully monitored. The prognosis for these children has greatly improved and some of them lead a normal life with nightly assisted ventilation at home.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8133976     DOI: 10.1055/s-2008-1071563

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  3 in total

1.  Congenital central hypoventilation syndrome (Ondine's curse syndrome) in two siblings: delayed diagnosis and successful noninvasive treatment.

Authors:  R Kerbl; H Litscher; H M Grubbauer; F Reiterer; G Zobel; M Trop; B Urlesberger; E Eber; R Kurz
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

Review 2.  Congenital central hypoventilation syndrome and Hirschsprung's disease.

Authors:  G D Croaker; E Shi; E Simpson; T Cartmill; D T Cass
Journal:  Arch Dis Child       Date:  1998-04       Impact factor: 3.791

3.  Unilateral ablation of pre-Botzinger complex disrupts breathing during sleep but not wakefulness.

Authors:  Leanne C McKay; Jack L Feldman
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.